This Article Full Text (PDF) All Versions of this Article: 1545109708315324v1 7/2/88    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tungsiripat, M. Articles by Aberg, J. Search for Related Content PubMed PubMed Citation Articles by Tungsiripat, M. Articles by Aberg, J. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                   What's this?

Prevalence and Significance of G6PD Deficiency in Patients of an Urban HIV Clinic

Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, tungsim{at}ccf.org

Henning Drechsler, MD

Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas TX, VA North Texas Health Care Center, Dallas, TX

Christine Sarlone, MD

University of Tennessee, Memphis

Kathleen Amyot, MD

Department of Family Practice, Saint Louis University/Scott AFB, St. Louis, MO

Elizabeth Laffey, MD

Department of Family Practice, Saint Louis University, St. Louis, MO

Judith Aberg, MD

New York University, New York, NY, AIDS Clinical Trials Unit, Seattle, WA, Bellevue Hospital Center, New York, NY

The rationale to screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency in HIV-infected individuals is their increased likelihood to receive oxidant drugs and subsequent potential of hemolytic events. However, current guidelines regarding who should be screened are conflicting. The authors examined the prevalence of G6PD deficiency and the frequency of hemolytic events in an urban HIV clinic. They used data from a military database as a comparison. In both cohorts, a relatively high number of black females were found to be G6PD deficient (10% and 13%), which was similar to the rate in men (15% and 12%). No white females were G6PD deficient. The authors identified 8 drug-related hemolytic events in HIV clinic patients. Two patients necessitated blood transfusions; both were triggered by trimethoprim/sulfamethoxazole (TMP/SMX). Although G6PD screening prior to the use of TMP/SMX is not often considered by clinicians, the authors' finding of 2 hemolytic events requiring transfusion suggests this would be beneficial.

Key Words: G6PD deficiency • HIV • screening • hemolytic anemia

This version was published on April 1, 2008

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 7, No. 2, 88-90 (2008)
DOI: 10.1177/1545109708315324


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?